Overview

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

Phase:

PHASE2

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Tirzepatide